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Abstract. In this study, 53 patients received piroxicam, administered orally or
sublingually, after undergoing removal of symmetrically positioned lower third
molars, during two separate appointments. This study used a randomized, blind,
cross-over protocol. Objective and subjective parameters were recorded for
comparison of postoperative results for 7 days after surgery. Patients treated with
oral or sublingual piroxicam reported low postoperative pain scores. The patients
who received piroxicam orally took a similar average amount of analgesic rescue
medication compared with patients who received piroxicam sublingually
(p > 0.05). Patients exhibited similar values for mouth opening measured just
before surgery and immediately following suture removal 7 days later (p > 0.05),
and showed no significant differences between routes of piroxicam administration
for swelling control during the second or seventh postoperative days (p > 0.05). In
summary, pain, trismus and swelling after lower third molar extraction, independent
of surgical difficulty, could be controlled by piroxicam 20 mg administered orally or
sublingually and no significant differences were observed between the route of
delivery used in this study.0901-5027/030292 + 06 $36.00/0 # 2010 International Association of Oral and Maxillofacial SurgeP. A. K. Trindade, F. P. M. Giglio,
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Available online 8 December 2010Pain resulting from the trauma of lower
third molar surgery has been studied
extensively and has become an established
model to evaluate the efficacy of many
pharmacological analgesics. Frequently,
this pain is moderate and temporary. Pain
from lower third molar extraction reachesits maximum intensity 2–4 h after the end
of surgery, and, in most cases, patients
require analgesic treatment26. Besides
pain, swelling and the limited articulation
of the temporomandibular joint associated
with inflammation, there are further unde-
sirable consequences for patients whoundergo surgical interventions in the oral
cavity6,11,37. Treatment for pain, trismus
and swelling after lower third molar sur-
gery includes non-steroidal anti-inflam-
matory drugs (NSAIDs)1,6,36,37. Most
NSAIDs function by inhibiting cycloox-
ygenase (COX) and thus, among otherons. Published by Elsevier Ltd. All rights reserved.
Oral and sublingual piroxicam efficacy 293actions, ultimately result in an inhibition
of prostaglandin production15,17,25.
Three isoforms of COX are known.
COX-1 is a constitutive form expressed
in almost all tissues. COX-2, also known
as prostaglandin-endoperoxide synthase 2
(PTGS2), is predominantly induced and
constitutively expressed in a limited num-
ber of tissues (renal medulla, prostate,
brain and endothelium)15,17,22,25,32. The
isoenzyme COX-2 stimulates the synth-
esis of pro-inflammatory prostaglan-
dins6,15,25,37. COX-3, a COX-1-derived
protein, is most abundant in the cerebral
cortex and heart1,4,32. COX-3 inhibition
may represent the primary central
mechanism by which NSAIDs such as
acetaminophen and dipyrone decrease
pain and possibly fever4,8. In accordance
with their relative inhibition of COX iso-
enzymes, NSAIDs can be classified as
nonselective, COX-2 preferential or
COX-2 selective7,31.
Numerous studies have evaluated the
efficacy of the more traditional NSAIDs,
including diclofenac, ibuprofen, meloxi-
cam, piroxicam and ketorolac, which are
all nonselective for COX-2 inhibition, and
valdecoxib, celecoxib, rofecoxib and etor-
icoxib, which are all selective for COX-2
inhibition. NSAIDs were administered
orally in all of these studies1,5,6,9,20,24,25.
NSAIDs have also been administered
sublingually. Sublingual administration of
a drug can relieve pain faster than oral
administration because this route avoids
the first passage of the drug in the liver
where some of the drug is metabolized.
Sublingual administration of NSAIDs18
may relieve pain faster than oral admin-
istration because the drug is absorbed by
the veins in the floor of the mouth, leading
directly to the superior vena cava, thus
resulting in faster distribution of the drug
to all tissues through the bloodstream.
Drugs administered orally circulate
through the bloodstream via the inferior
vena cava, which takes longer to distribute
the drug to all tissues compared with
sublingual administration. Orally adminis-
tered NSAIDs must pass through the caus-
tic environment of the gastrointestinal
tract; sublingual administration avoids
the gastrointestinal tract.
Little clinical research has investigated
the efficacy of administering the nonse-
lective COX-2 inhibitor NSAID, piroxi-
cam, to control pain, trismus and swelling
resulting from the trauma of lower third
molar surgery. This surgical procedure is a
well accepted model used to evaluate the
clinical efficacy of anesthetics and anti-
inflammatory drugs1,3,5. When patients
receive no analgesic medication theyreport a pain score of 80 on a visual analog
scale (VAS) from 0 to 100 cm with zero
representing ‘no pain’ and 100 represent-
ing ‘the worst pain imaginable’3,28. It is
necessary to manage pain for this surgery
and this study did not use a placebo as a
negative control.
The same surgical procedure was per-
formed on both sides of the jaw on two
separate occasions in the same patient,
then each side of the jaw was compared
with the other to avoid individual varia-
tions12,21. In this way each patient served
as his or her own control. This study
compared the clinical efficacy of piroxi-
cam orally or sublingually in managing
pain after lower third molar removal.
Materials and methods
The Institutional Ethics Committee
approved the protocol of this study
(#108/2007). All 53 study patients pro-
vided written informed consent during
the pre-treatment screening period. Elig-
ibility criteria included patients aged 18
years or older who had two lower third
molars in a similar position as observed
using panoramic radiography. Exclusion
criteria included: systemic illness and
inflammation or infection at the extraction
sites; any history of allergic reaction to
local anesthetic; gastrointestinal bleeding
or ulceration; cardiovascular and hepatic
diseases; and allergy to aspirin, piroxicam
or any other NSAID. Pregnant women
were excluded from the study. Instructions
for not using antidepressants, diuretics,
aspirin or antibiotics 7 days prior to sur-
gery were given to the patients, avoiding
possible hemorrhage or other possible
unwanted interactions with the drugs used
in this investigation3,5,6,11,19,34.
This research was a randomized, blind,
cross-over study. Only one side of the
mandibular jaw was operated on at a time.
The surgery was performed over the
course of two visits separated by 1–2
months3,5,6,11,19,34. During each patient’s
first appointment he or she randomly
received either piroxicam orally or sub-
lingually for postoperative pain relief (a
coin was flipped to determined the route of
delivery). During the patient’s second
appointment, the route of administration
not used previously was administered in a
crossover manner. Each patient remained
unaware of how piroxicam would be
administered until after their first surgery
was completed. The surgeon was blinded
to the delivery route of piroxicam. The
entire dataset was analyzed by a third
researcher naive to how pain was managed
for each molar extraction.One surgeon performed all operations
and postoperative controls. All patients
received local anesthetic blockade of buc-
cal, lingual and inferior alveolar nerves via
1.8 ml of 4% articaine with 1:200,000
adrenaline34. When anesthesia of the
inferior lip was achieved, an additional
0.9 ml of the same anesthetic was injected
into the mucosa to guarantee hemostasis
and anesthesia of the site. The removal of
every third molar followed a standard
surgical protocol34. Immediately follow-
ing the extraction, each surgical site was
thoroughly irrigated, suctioned,
sutured6,11 and the patient was given pir-
oxicam orally or sublingually by a second
dentist. Patients remained in the clinic for
the first postoperative hour. During this
time the local anesthetic blockade was still
present. The aim of this study was to
investigate and compare the efficacy of
piroxicam administered orally or sublin-
gually to guarantee a painless postopera-
tive period. It was not the aim of this study
to determine or compare the onset of pain
management by piroxicam administered
orally or sublingually.
Each patient experienced approxi-
mately the same magnitude of surgical
trauma on each side of the mandibular
jaw. The surgical trauma varied, however,
with some patients requiring osteotomy
during both surgeries. The study patients
were subdivided into those who received
osteotomy and those who did not.
The NSAID administration protocol
was one 20 mg capsule of piroxicam taken
orally or one 20 mg tablet of fast-dissol-
ving dosage form piroxicam taken sublin-
gually once daily for 4 days. Previous
studies have shown that 20 mg of pirox-
icam effectively manages postoperative
pain with few or no side
effects3,14,18,29,30,33,35; whereas piroxicam
doses less than 20 mg (e.g. 5 mg or 10 mg)
were ineffective in managing postopera-
tive pain14. Oral rescue analgesic medica-
tion was available to any patient as needed
throughout the study; for this purpose,
750 mg tablets of paracetamol were pro-
vided to all patients3,5,6,11,19,34. Patients
recorded the date and time at which rescue
medication was consumed. They were
instructed not to interrupt the use of the
principal medication, even if they had
consumed rescue analgesic medication.
Duration of surgery (min) after anes-
thetic administration, specifically, the per-
iod between the first incision and the last
suture was recorded6,11,37. Subjective
postoperative pain evaluations were docu-
mented, with the aid of a 100 mm
VAS6,11,13. The intensity of postoperative
pain was chronicled at 15-min intervals for
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Fig. 1. Mean pain scores (in mm) recorded by patients (n = 21 without osteotomy and n = 32
with osteotomy), with the aid of a 100 mm VAS at 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10,
12, 16, 24, 48, 72 and 96 h after the end of surgery for lower third molar extraction. Two
administration routes of 20 mg of piroxicam, oral or sublingual, for 4 postoperative days, were
used in a randomized, blind, crossover manner. Data are represented as means  1 SEM.the first 60 postoperative minutes, and 1.5,
2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 48, 72 and
96 h after the end of the surgery as eval-
uated by the patients3,5,10,11,19,34. Time (h)
to first rescue analgesic medication and
total amount (mg) of rescue analgesic
medication ingested during the postopera-
tive period were documented by each
patient. Mouth opening (distance in mm)
between the mesial–incisal corners of the
upper and lower right central incisors at
maximum opening of the jaws was mea-
sured and recorded before surgery, during
the second postoperative day and at the
moment of suture removal (seventh post-
operative day). The postoperative ability
to open the mouth was expressed as a
percentage of preoperative measure-
ments11,37. Facial swelling was measured
and recorded during the second and
seventh postoperative days37. This pro-
duced a single value for each patient,
which is the sum of the following mea-
surements: the distance (mm) between the
lateral corner of the eye and the angle of
the mandible; the distance (mm) between
the tragus and the outer corner of theTable 1. Consumption of rescue analgesic medi
third molars.
Total amo
With osteotom
Oral piroxicam 1,928.57  355
Sublingual piroxicam 1,750.00  312
No significant differences were found betweenmouth; and the distance (mm) between
the tragus and the soft tissue pogonion.
The preoperative sum of these three mea-
surements was considered the baseline
value. The difference between the sum
of the postoperative measurements and
the baseline value indicated the facial
swelling for that day. Incidence, type
and severity of adverse reactions (gastro-
intestinal irritation, nausea, vomiting,
bleeding, allergy, headache, dizziness,
sleepiness and any other kind of reaction)
were documented by each patient13. Glo-
bal evaluations of piroxicam’s efficacy
during the seventh postoperative day were
rated using a five level Likert scale by
volunteers who received sublingual and
oral piroxicam (20 mg). The format of
the Likert items was: excellent, very good,
good, fair or poor23.
Paired t-tests were used to compare the
duration of the entire surgeries. The non-
parametricWilcoxon test was employed to
assess the parameters ‘postoperative pain’
and ‘rescue analgesic medication’. Data
regarding ‘mouth opening’ and ‘facial
swelling’ were tested and confirmed forcation (paracetamol) recorded for comparison of
unt of rescue medication (mg)
y Without osteotomy W
.61 892.86  270.20 1
.71 607.14  179.42 1
piroxicam administered orally and sublingually (normal distribution and the values were
compared using an ANOVA followed by
Tukey’s test for multiple comparisons.
Statistical significance was set at
p < 0.05. Data are represented as a mean
 standard error of the mean.
Results
There were 53 volunteers (15 male and 38
female, mean age 22 years) in this study.
The participants were also subdivided into
two subgroups: 21 patients without osteot-
omy and 32 with osteotomy. Surgery
requiring osteotomy lasted
20.61  1.49 min and 17.41  1.48 min
for patients taking piroxicam orally and
sublingually, respectively, and for patients
not requiring osteotomy the surgery lasted
10.05  0.39 min and 9.95  0.29 min,
for the same groups, respectively. No
significant differences in the mean dura-
tion of the two surgeries in each patient
were observed (p > 0.05). There was a
significant difference in the mean duration
of operations performed with and without
bone removal (p < 0.05), indicating that
surgery involving the more time consum-
ing osteotomy was more aggressive. Over-
all the duration of surgery was short.
In the postoperative pain scores, docu-
mented by each patient, no significant
differences were observed between the
two routes of piroxicam administration
(p > 0.05) (Fig. 1). All scores of pain
recorded in both studies were small.
The amount of analgesic rescue medi-
cation taken by patients was small and no
differences were observed between
patients given piroxicam orally or sublin-
gually, irrespective of the necessity for
bone removal (Table 1). There was no
significant difference in the time of inges-
tion of the first rescue medication when
patients were medicated with piroxicam
either orally or sublingually, in both sub-
groups (p > 0.05, Table 1).
There was only a major limitation of the
patients’ mouth opening during the second
day. During the seventh day following
surgery, the values for mouth opening
measurements returned to baseline values
(p > 0.05, Table 2). Similar mouth open-
ings were recorded during the second andpostoperative courses after removal of lower
Time to first rescue medication (h)
ith osteotomy Without osteotomy
2.08  6.03 3.34  1.67
2.85  3.83 9.78  4.90
p > 0.05).
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Table 2. Mouth opening and swelling recorded for comparison of postoperative courses after lower third molar extraction.
Mouth opening
(%, 2nd
postoperative day)
Mouth opening
(%, 7th
postoperative day)
Swelling
(mm, 2nd
postoperative day)
Swelling
(mm, 7th
postoperative day)
With
osteotomy
Without
osteotomy
With
osteotomy
Without
osteotomy
With
osteotomy
Without
osteotomy
With
osteotomy
Without
osteotomy
Oral piroxicam 74.17  4.5879.92  4.4491.53  4.3996.90  2.2233.86  5.9316.19  5.866.24  4.343.62  9.05
Sublingual piroxicam74.57  4.1779.93  4.2292.34  2.7096.89  2.3330.24  8.4521.00  8.247.05  7.212.52  5.24
No significant differences were found between piroxicam administered orally and sublingually (p > 0.05).seventh postoperative days between the
preoperative measurements for patients
taking either oral piroxicam or sublingual
piroxicam. No significant differences in
the mouth opening parameters were
observed between the groups with and
without osteotomy.
A similar result was observed for the
values taken for swelling during the sec-
ond and seventh day after surgery. Patients
showed no significant differences between
the groups. Swelling tended to be
increased during the second day, but
returned to baseline measurements during
the seventh day (p > 0.05, Table 2); this
increase in swelling was not statistically
significant and was the same regardless of
the drug delivery route.
Six patients had gastric discomfort
when oral piroxicam was used and one
patient had gastric discomfort with sub-
lingual piroxicam. Two patients noted
sleepiness with oral piroxicam and two
with sublingual piroxicam.
According to the patients’ global eva-
luations of their postoperative period pir-
oxicam administered by either route was
classified as good, very good and excellent
for most patients. Four patients who took
oral piroxicam and two patients who took
piroxicam sublingually classified the per-
iod as fair when osteotomy was necessary
and one patient, in the same subgroup,
[()TD$FIG]
Fig. 2. Global evaluations of piroxicam’s effica
rated using a five level Likert scale by voluntee
piroxicam (20 mg). The format of the Likert item
The patients’ ratings of piroxicam’s efficacy dur
molar extraction were collated and represented b
Sublingual piroxicam and oral piroxicam werewho took oral piroxicam, classified the
period as poor (Fig. 2).
Discussion
This study investigated the clinical effi-
cacy of the NSAID, piroxicam, which was
administered either orally or sublingually,
after the lower third molar was extracted
under local anesthesia. The degree of dif-
ficulty of the surgical procedure and the
local trauma caused by the surgery varied
among the patients, and depended on
whether it was necessary to remove bone
tissue to extract the lower third molars.
Surgical trauma on either side of the jaw in
each patient was not significantly different
but there was a difference between those
who received osteotomy and those who
did not. The establishment of two sub-
groups (with or without osteotomy)
assured that the sole variable in this study
would be the route of drug delivery. This
allowed the comparison of the efficacy of
each delivery route for managing post-
operative pain, trismus and swelling.
The method employed in this study to
measure swelling is widely accepted in the
literature18,37. The benefits of this method
lie in its simplicity. It is non-invasive, cost
effective, timesaving, and provides
numeric data for the determination of
soft-tissue contour changes. The resultscy during the seventh postoperative day were
rs (n = 53) who received sublingual and oral
s was: excellent, very good, good, fair or poor.
ing this postoperative period after lower third
y two bar charts, with and without osteotomy.
depicted as two separate datasets.of this protocol showed changes in facial
soft-tissue contours during the second and
seventh postoperative days corroborating
the results observed by CALVO et al.5
(meloxicam) and GRAZIANI et al.18 (pirox-
icam). On the seventh postoperative day,
for both groups, the magnitude of swelling
was far less than that observed on the
second postoperative day, with measures
lower than baseline values. These findings
could be because patients lost weight dur-
ing the postoperative period, causing
changes in facial soft-tissue contours, or
due to the fact that the method employed is
not as accurate as a computed tomography
scan or magnetic resonance imaging for
precise measurement of facial soft
volume.
Mouth opening (closely related to swel-
ling) in the two postoperative periods was
the same among all groups. These data are
in agreement with other studies that used
other NSAIDs5,6,11,18, which showed the
effectiveness of NSAIDs in controlling
pain, swelling and trismus after lower
third molar extraction.
In this study, the route of NSAID deliv-
ery was not related to the efficacy of
piroxicam on the management of post-
operative pain, trismus and swelling when
the lower third molar was extracted. In
theory, sublingual administration should
have had a significantly faster onset of
action compared with oral administration.
In a different experimental protocol this
could improve pain relief in the postopera-
tive period, yet in the present study it was
not possible, nor was it the aim, to com-
pare the onset of pain relief by piroxicam
since patients were still under the effects
of local anesthesia from the surgery.
Patients were given piroxicam immedi-
ately following the end of surgery34. Both
delivery methods used in this study
relieved pain before the effects of the local
anesthetic dissipated.
NSAIDs including piroxicam are not
completely free of adverse effects. Some
individuals exhibit allergic reactions to
NSAIDs. Patients with an increased risk
for hepatic failure16,27, peptic ulcers16, and
gastrointestinal inflammation16 should
296 Trindade et al.avoid using NSAIDs, including piroxi-
cam. According to one datasheet for pir-
oxicam ‘approximately 30% of all
patients receiving daily doses of 20 mg
of piroxicam experience[d] [adverse] side
effects’, the most common side effects
were typically mild including: abdominal
discomfort (6%), flatulence (5%), nausea
(5%), abdominal pain (5%), epigastric
distress (5%), constipation (4%), and
diarrhea (3%)16. Some of the more rare
side effects such as gastrointestinal bleed-
ing (0.1%) and peptic ulceration (2%) are
more dangerous, and in some of these
remote cases these side effects were
severe enough to cause death16. Conse-
quently, patients were excluded from this
study if they had a history of: allergic
reactions to any analgesic drugs including
NSAIDs; gastrointestinal bleeding or
ulcerations; or cardiovascular or hepatic
diseases.
There are conflicting statements about
the adverse side effects of 20 mg of oral
piroxicam. BARROSO et al. reported a sig-
nificant increase in the number of patients
who reported adverse side effects when
they received 20 mg of oral piroxicam
daily for 4 days compared with oral Rheu-
mazin1 (10 mg piroxicam, 1 mg dexa-
methasone, 35 mg orphenadrine citrate,
2.5 mg cyanocobalamin)2. In this case
there were 10 reports of adverse side
effects in the 41 patients tested with
20 mg of piroxicam. OHNISHI et al.
reported few adverse side effects30. Spe-
cifically, when patients received 20 mg of
oral piroxicam daily for 5 days only 4 of
84 patients experienced adverse side
effects and none were ‘serious or unu-
sual’30. DESJARDINS14 evaluated the inci-
dence of the adverse effects of piroxicam
in 798 patients from 5 studies and con-
cluded that ‘a wide range of piroxicam
doses are safe when administered in single
doses for the treatment of acute dental
pain’.
This study confirmed the hypothesis
that piroxicam administered orally or sub-
lingually would effectively control inflam-
mation and the onset of pain after lower
third molar removal. The quantification of
pain scores by VAS, the amount of rescue
medication taken by patients and the glo-
bal evaluation of the drug by the patients
remained the same regardless of the route
of delivery of piroxicam. In every para-
meter tested, when piroxicam was admi-
nistered orally or sublingually no
significant differences were observed.
In conclusion, postoperative pain, tris-
mus and swelling in patients subjected to
lower third molar extraction can be con-
trolled successfully by 20 mg of piroxi-cam administered either orally or
sublingually.
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